By targeting PDGFR, CSF1R, and c-KIT, seralutinib could lead to the reverse remodeling of pulmonary vascular disease in PAH, with a consequent improvement in clinically meaningful outcomes with a limited risk for adverse events. The gene discussed is KIT; the disease is pulmonary arterial hypertension.